Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE